Shaanxi Kangjun Biotechnology

Shaanxi Kangjun Biotechnology is a clinical-stage biopharmaceutical company based in Xi'an, China, specializing in the development of innovative peptide-based therapeutics. The company focuses on addressing the global challenge of antibiotic resistance by leveraging its proprietary peptide discovery and optimization platform to create next-generation anti-infective agents. Its lead candidate, KJ-M9, is a novel antimicrobial peptide designed for the treatment of skin and soft tissue infections, including those caused by multi-drug resistant pathogens like MRSA. Beyond anti-infectives, the company is exploring applications in wound healing and other inflammatory conditions. Kangjun Biotechnology has secured significant venture capital funding to advance its pipeline through clinical development.